E-LIB Suche - Ergebnisse für: van den Berg, Sibren

1

Reliable business case for repurposing of existing medicine..:

de Visser, Samuel J. ; van den Berg, Sibren ; Mosterd, Arend.
Drug Discovery Today. 29 (2024) 9 - p. 104096 , 2024

Link: https://doi.org/10.1016/..

2

Access to medicines for rare diseases: A European regulator..:

Rosenberg, Noa ; van den Berg, Sibren ; Stolwijk, Nina N....
Frontiers in Pharmacology. 14 (2023) - p. , 2023

Link: https://doi.org/10.3389/..

3

Development of medicines for rare diseases and inborn error..:

Rosenberg, Noa ; Stolwijk, Nina N. ; van den Berg, Sibren...
Journal of Inherited Metabolic Disease. 46 (2023) 5 - p. 806-816 , 2023

Link: https://doi.org/10.1002/..

4

PP152 The Assessment Of The Price Of A Medicine: The Possib..:

Van Den Berg, Sibren ; Canoy, Marcel ; Timmers, Lonneke.
International Journal of Technology Assessment in Health Care. 38 (2022) S1 - p. S89-S90 , 2022

Link: https://doi.org/10.1017/..

5

Towards sustainability and affordability of expensive cell ..:

Thielen, Frederick W. ; Heine, Renaud J.S.D. ; Berg, Sibren van den..
Cytotherapy. 24 (2022) 12 - p. 1245-1258 , 2022

Link: https://doi.org/10.1016/..

6

Author Reply:

van den Berg, Sibren ; de Visser, Saco J. ; Timmers, Lonneke.
Value in Health. 25 (2022) 1 - p. 158-159 , 2022

Link: https://doi.org/10.1016/..

7

Modified Delphi procedure-based expert consensus on endpoin..:

Schoenmakers, Daphne H. ; Beerepoot, Shanice ; van den Berg, Sibren...
Orphanet Journal of Rare Diseases. 17 (2022) 1 - p. , 2022

Link: https://doi.org/10.1186/..

8

Effectiveness and safety of mexiletine in patients at risk ..:

van der Ree, Martijn H ; van Dussen, Laura ; Rosenberg, Noa...
EP Europace. 24 (2022) 11 - p. 1809-1823 , 2022

Link: https://doi.org/10.1093/..

9

Cost-Based Price Calculation of Mexiletine for Nondystrophi..:

van den Berg, Sibren ; van der Wel, Vincent ; de Visser, Saco J....
Value in Health. 24 (2021) 7 - p. 925-929 , 2021

Link: https://doi.org/10.1016/..

10

Drug Repurposing for Rare Diseases: A Role for Academia:

van den Berg, Sibren ; de Visser, Saco ; Leufkens, Hubert G.M..
Frontiers in Pharmacology. 12 (2021) - p. , 2021

Link: https://doi.org/10.3389/..

11

Registries for orphan drugs: generating evidence or marketi..:

Hollak, Carla E. M. ; Sirrs, Sandra ; van den Berg, Sibren...
Orphanet Journal of Rare Diseases. 15 (2020) 1 - p. , 2020

Link: https://doi.org/10.1186/..

12

Access to medicines for rare diseases: A European regulator..:

Rosenberg, Noa ; van den Berg, Sibren ; Stolwijk, Nina N...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012277/. , 2023

Link: http://www.ncbi.nlm.nih...

13

Access to medicines for rare diseases:A European regulatory..:

Rosenberg, Noa ; van den Berg, Sibren ; Stolwijk, Nina N...
https://research.rug.nl/en/publications/cc1a4401-a1ab-4fc1-a7b6-b0be3cab61c7. , 2023

Link: https://hdl.handle.net/1..

14

Modified Delphi procedure-based expert consensus on endpoin..:

Schoenmakers, Daphne H ; Beerepoot, Shanice ; van den Berg, Sibren...
1750-1172. , 2022

Link: https://dspace.library.u..

15

Effectiveness and safety of mexiletine in patients at risk ..:

van der Ree, Martijn H ; van Dussen, Laura ; Rosenberg, Noa...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681134/. , 2022

Link: http://www.ncbi.nlm.nih...